Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with type 2 diabetes, currently treated with insulin glargine or other intermediate- or long-acting insulin, with or without oral antidiabetic medications, but experiencing inadequate glycemic control and willing and capable of participating in a regimen of intensive insulin administration. A subject who has been on an intermediate- or long acting insulin for \>/=6 months but \<5 years, and, in spite of dosage adjustments based on home blood glucose monitoring, is unable to achieve a HbA1c of \<7%.~* BMI \>/= 20kg/m2 and \</=45 kg/m2~* Fasting C-peptide \>/=0.8 ng/mL (\>/= 0.26 nmol/L)~* HbA1c between 7.0% and 10.5%, inclusive~* Use of oral or systemically injected glucocorticoids is generally not allowed within 3 months before randomization; inhaled, intra articular, and topical corticosteroids are allowed~* Hemoglobin \</=11 g/dL for male subjects and \>/=10 g/dL for female subjects~* Creatinine clearance \>60 mL/min (calculated using the Cockcroft Gault formula)~* Thyroid stimulating hormone level is normal or clinically euthyroid as demonstrated by further thyroid tests (e.g., T4, T3, thyroid-binding globulin)~* Female subjects of childbearing potential (i.e., not surgically sterile and/or not postmenopausal) must be practicing adequate contraception. Adequate contraception must be practiced for the duration of participation in the study including the 8 week Posttreatment Follow-up Period~* Able and willing to monitor his or her own blood glucose concentrations with a home glucose monitor as per the protocol recommendations of self administration~* No major illness or debility that in the investigator's opinion prohibits the subject from actively participating in their diabetes management and completing the study~* Able and willing to provide written informed consent~Exclusion Criteria:~* History of cancer, other than squamous cell or basal cell carcinoma of the skin, that has not been in full remission for at least 3 years before Screening.~* History of treated diabetic gastroparesis~* Current ongoing symptomatic biliary disease or history of pancreatitis~* History of significant gastrointestinal surgery, including gastric bypass and banding, antrectomy, Roux en Y bypass, gastric vagotomy, small bowel resection, or surgeries thought to significantly affect upper gastrointestinal function~* Recent clinically significant cardiovascular and/or cerebrovascular disease including but not limited to the following:~  * Previous history of stroke or transient ischemic attack within 1 month before Screening.~ * Acute coronary syndrome, which includes the following:~ * Documented MI within the 2 months before Screening and during the period up until receiving the first dose of study medication~ * Any cardiac surgery including percutaneous transluminal coronary angioplasty, coronary stent placement, or coronary artery bypass graft surgery within the 2 months before Screening and during the period up until receiving the first dose of study medication~ * Unstable angina not responsive to nitroglycerin within the 2 months before Screening and during the period up until receiving the first dose of study medication~ * Unstable cardiac rhythm, however, as an example, controlled atrial fibrillation is allowed~ * Current or history of heart failure (New York Heart Association class I to IV).~ * Resting systolic pressure is \>160 mm Hg and/or diastolic pressure \>100 mm Hg.~ * QTc interval (Fridericia) \>470 ms confirmed by a central reader at Screening~* History of stroke or other central nervous system disorder that would negatively impact the subject's ability to participate in a program of intensive insulin management (eg, physically or mentally incapable of performing home blood glucose monitoring or administering and/or adjusting insulin dosage)~* Hemoglobinopathy that may affect determination of HbA1c~* History of human immunodeficiency virus infection~* History of total bilirubin \>1.5 × ULN unless the subject has a previously known history of Gilbert's syndrome and a fractionated bilirubin that shows conjugated bilirubin \<35% of total bilirubin~* ALT or aspartate aminotransferase (AST) \>2.5 ×ULN~* Fasting triglyceride level \>850 mg/dL at Screening or Week -1 (Visit 5).~* Acute symptomatic (within 3 months before Screening) infection with hepatitis B or hepatitis C; however, subjects with past or chronic hepatitis B or hepatitis C are allowed provided the requirements for ALT, AST, and total bilirubin are met~* History of a psychiatric disorder that will affect the subject's ability to participate in the study~* History of alcohol or substance abuse within 1 year before Screening~* Positive urine drug screen at Screening, unless the subject is taking a medically approved medication for which a positive drug screen simply verifies the use of this medication~* Hypoglycemia unawareness which has impaired cognitive function and required outside assistance~* Female subject is pregnant (confirmed by laboratory testing), lactating, or \<6 weeks postpartum~* Known allergy to any GLP 1 analogue, insulin, other study medications' excipients, excipients of albiglutide, or Baker's yeast~* Receipt of any investigational drug within the 30 days, or 5 half lives whichever is longer, before Screening or a history of receipt of an investigational antidiabetic drug within the 3 months before randomization, or receipt of albiglutide in previous studies~* Current use of any GLP 1 analogue~* History of type 1 diabetes mellitus, diabetic complications (e.g., active proliferative retinopathy or severe diabetic neuropathy) that in the opinion of the investigator would preclude effective participation in the study, or a history of ketoacidosis or hyperosmolar coma~* Contraindications (as per the prescribing information) for the use of either background or potential randomized study medications (e.g., insulin glargine or lispro insulin)~* History or family history of medullary carcinoma~* History or family history of multiple endocrine neoplasia type 2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- albiglutide + insulin glargine (Type: ACTIVE_COMPARATOR): albiglutide in combination with insulin glargine
- insulin glargine + preprandial lispro insulin (Type: ACTIVE_COMPARATOR): insulin glargine in combination with preprandial lispro insulin

Based on this trial design, predict the completion outcome and termination type (if applicable).